Fundraising Fox
BioAtla
San Diego, US · Founded 2007 · 32 employees on LinkedIn · 11 known investors
Find your way into BioAtla
Sign up to see every warm intro you have to BioAtla
- Paths you didn't know you had: your email and LinkedIn already hold routes to the BioAtla team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
BioAtla develops novel monoclonal antibody and cell-based therapeutics for cancer treatment using proprietary platforms including Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!). The company aims to create biologics with improved selectivity for tumor tissue and enhanced therapeutic index.
Founders & leadership
BioAtla was founded in 2007 by Jay M. Short.
Investors · 11
How we know: Keshif Ventures's portfolio page · Not right? Tell us
How we know: Pappas Capital's portfolio page · Not right? Tell us
How we know: Pfizer Venture Investments's portfolio page · Not right? Tell us
How we know: prnewswire.com · Not right? Tell us
How we know: prnewswire.com · Not right? Tell us
How we know: prnewswire.com · Not right? Tell us
Also in the syndicate · 4
Funding
SEC filings, press & company announcements$44.8M disclosed across 2 of 4 rounds · 2014–2024
- Undisclosed amountregistered direct offeringDec 2024Source ↗
- Undisclosed amountSeries DJul 2020
HBM Healthcare Investments (lead), Soleus Capital (lead), Boxer Capital, Cormorant Asset Management, Farallon Capital, Janus Henderson, Pappas Capital, Pfizer Ventures
Source ↗
▶$39MraisedJul 2015 · 3 investors · BiotechnologyRule 506(b)
- Jay M. ShortExecutive Officer, Director
- Carolyn ShortDirector
- Richard A. WaldronExecutive Officer
- Offering amount
- $39M
- Amount sold
- $39M
- Proceeds to insiders
- $4.4M
- First sale
- Mar 2015
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$5.8MraisedJul 2015 · 53 investors · BiotechnologyRule 506(b)
- Jay M. ShortExecutive Officer, Director
- Richard A. WaldronExecutive Officer
- Carolyn ShortDirector
- Offering amount
- $5.8M
- Amount sold
- $5.8M
- First sale
- Apr 2014
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $220.3K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does BioAtla do?
- BioAtla develops novel monoclonal antibody and cell-based therapeutics for cancer treatment using proprietary platforms including Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!). The company aims to create biologics with improved selectivity for tumor tissue and enhanced therapeutic index.
- Who founded BioAtla?
- BioAtla was founded by Jay M. Short in 2007.
- Who are BioAtla's investors?
- BioAtla's investors include Keshif Ventures, Pappas Capital, Pfizer Venture Investments, HBM Healthcare Investments, Pappas Capital, Pfizer Ventures, Soleus Capital.
- How much funding has BioAtla raised?
- BioAtla has disclosed $44.8M raised across 2 of its 4 known rounds.
- Where is BioAtla headquartered?
- BioAtla is headquartered in San Diego, US.